February 26, 2024
Interchangeable Humira Biosimilar Simlandi Joins Market Battle with Unique High-Concentration Formula
Simlandi, interchangeable, Biosimilars, Market
Johnson & Johnson Closes Bay Area R&D Facility, Plans New California Innovation Center
Research and Development, Johnson and Johnson, California, Central
FDA Approves Allecra’s Exblifep, Giving Headstart Over Competition in Complicated Urinary Tract Infections
Urinary tract infection, Complicated
Venatorx Confident in Quick Resolution of Manufacturing Concerns for Cefepime-Taniborbactum Antibiotic Despite FDA Setback
United States Food and Drug Administration, Venatorx, CID, 2024-02-23, cefepime-taniborbactam, Manufacture